Indimitecan structure
|
Common Name | Indimitecan | ||
|---|---|---|---|---|
| CAS Number | 915360-05-3 | Molecular Weight | 459.45100 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C25H21N3O6 | Melting Point | N/A | |
| MSDS | N/A | Flash Point | N/A | |
Use of IndimitecanIndimitecan (LMP776) is a topoisomerase I (Top1) inhibitor with anticancer activities[1]. |
| Name | indimitecan |
|---|---|
| Synonym | More Synonyms |
| Description | Indimitecan (LMP776) is a topoisomerase I (Top1) inhibitor with anticancer activities[1]. |
|---|---|
| Related Catalog | |
| Target |
Top1 |
| In Vitro | Indimitecan (LMP776) (0-100 μM) shows antiproliferative potencies against various human cancer cell lines, with mean-graph midpoint (MGM) of 0.079 ± 0.023 μM[1]. Indimitecan shows potent DNA cleavage due to Top1 inhibition[1]. Indimitecan can be substrates for metabolic ketone reductases[1]. Cell Proliferation Assay[1] Cell Line: HOP-62, HCT-116, SF-539, UACC-62, OVCAR-3, SN12C, DU-145, MCF-7 Concentration: 0-100 μM Incubation Time: Result: Showed growth inhibition with GI50s of <0.01, <0.01, 0.04, <0.01, 0.08, <0.01, <0.01 and 0.01 μM against HOP-62, HCT-116, SF-539, UACC-62, OVCAR-3, SN12C, DU-145 and MCF-7 cells, respectively. And the mean-graph midpoint (MGM) for growth inhibition of all human cancer cell lines successfully tested (the National Cancer Institute’s developmental therapeutics assay (the “NCI60”)) was 0.079 ± 0.023 μM. |
| References |
| Molecular Formula | C25H21N3O6 |
|---|---|
| Molecular Weight | 459.45100 |
| Exact Mass | 459.14300 |
| PSA | 93.81000 |
| LogP | 3.24560 |
| UNII-V5T7S4HP8A |
| 5H-(1,3)Dioxolo(4',5':5,6)indeno(1,2-c)isoquinoline-5,12(6H)-dione,6-(3-(1H-imidazol-1-xyl)propyl)-2,3-dimethoxy |